Improving immunotherapy in solid tumors using FMT.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 41997122.
- Also identified by DOI 10.1016/j.cell.2026.03.021.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Recent clinical trials demonstrate that fecal microbiota transplantation (FMT) enhances first-line immune checkpoint inhibitor efficacy in renal cell carcinoma, cutaneous melanoma, and non-small cell lung cancer with acceptable safety. Benefit appears mediated by functional microbiome remodeling, depletion of deleterious taxa, and systemic immunometabolic modulation, supporting microbiome-directed therapeutic strategies for cancer immunotherapy.
Medical subject headings
- Immunotherapy
- Fecal Microbiota Transplantation
- Neoplasms